Brief: Alzamend Neuro Receives FDA “Study May Proceed” Notification for Phase IIA Clinical Trial of AL001

Alzamend Neuro

20/11/2023 13:17

Nov 20 (Reuters) - Alzamend Neuro Inc  ALZN.O :
    * ALZAMEND NEURO RECEIVES FDA “STUDY MAY PROCEED”
NOTIFICATION FOR
A PHASE IIA CLINICAL TRIAL OF AL001, A NEXT-GENERATION LITHIUM
THERAPEUTIC DRUG CANDIDATE, IN MAJOR DEPRESSIVE DISORDER
PATIENTS
    * ALZAMEND NEURO INC - EXPECT THAT FIRST PATIENT WILL BE
DOSED IN
Q1 OF 2024

Source text for Eikon:  ID:nBw5lNDLsa 
Further company coverage:  ALZN.O 

 ((Reuters.Briefs@thomsonreuters.com;))